Search

Your search keyword '"Lafayette, Richard"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Lafayette, Richard" Remove constraint Author: "Lafayette, Richard" Journal kidney international reports Remove constraint Journal: kidney international reports
33 results on '"Lafayette, Richard"'

Search Results

2. A Focus Group Study of Self-Management in Patients With Glomerular Disease

3. Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy

6. Persistent Disease Activity in Patients With Long-Standing Glomerular Disease

7. WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN

8. WCN24-1688 SELF-REPORTED QUALITY OF LIFE IN COMPLEMENT 3 GLOMERULOPATHY PATIENTS DELINEATED BY CKD STAGE: A REAL-WORLD, MULTI-COUNTRY SURVEY

9. WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY

11. WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL

12. WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL

14. WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL

15. WCN24-1680 PREVALENCE AND CLINICAL CHARACTERISTICS OF KIDNEY TRANSPLANTS IN COMPLEMENT 3 GLOMERULOPATHY PATIENTS: RESULTS FROM A REAL-WORLD, MULTI-COUNTRY SURVEY

17. WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL

20. WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY

21. WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL

23. Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study

24. NephCure Accelerating Cures Institute: A Multidisciplinary Consortium to Improve Care for Nephrotic Syndrome

27. A Focus Group Study of Self-Management in Patients With Glomerular Disease

28. Why Target the Gut to Treat IgA Nephropathy?

29. Persistent Disease Activity in Patients With Long-Standing Glomerular Disease

32. Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study

33. An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression.

Catalog

Books, media, physical & digital resources